Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

)Department of Medicine,University of Cambridge School of Clinical Medicine,Cambridge, UKe-mail: jec1001@cam.ac.ukD. M. ReidUniversity of Aberdeen Medical School,Foresterhill,Aberdeen AB25 2ZD, UKJ. BoisdronHoffman-La Roche Ltd,Basle, SwitzerlandM.-L. BrandiMetabolic Bone Unit, Laboratory of Molecular Genetics,Department of Internal Medicine, University of Florence,Florence, ItalyN. BurletInternational Osteoporosis Foundation,Nyon, SwitzerlandD. CahallSanofi-Aventis,Bridgewater, NJ, USAP. D. DelmasUniversity of Lyon and INSERM Research Unit 831,Lyon, FranceW. DereAmgen,Thousand Oaks, CA, USAJ.-P. DevogelaerThe Arthritis Unit, Universite Catholique de Louvain,Brussels, BelgiumL. A. FitzpatrickMedicines Disease Center, GlaxoSmithKline,King of Prussia, PA, USAB. FlamionLaboratory of Physiology and Pharmacology,University of Namur,Namur, BelgiumN. GoelClinical Development, UCB Inc.,Smyrna, GA, USA